Supplement encyclopedia

Curcuma longa

Turmeric is a plant whose rhizome is used as a spice and as a raw material for supplements.

Double-check the conclusions and read the sources before choosing a supplement.

Main conclusion

What it may offer

  • WDTE60N may reduce muscle pain during the first four days after strength exercise involving squats in moderately active adults aged 18–35. The product was taken at 250 mg a day for 33 days, starting before exercise.
  • Curcugen at 500 mg of product a day for eight weeks may slightly reduce overall digestive discomfort in adults with these complaints.
  • Curcugen showed no advantage over placebo for individual types of digestive complaints or overall quality of life.
  • WDTE60N may increase instrument-measured skin hydration in women aged 18–40 with facial spots. With 250 mg of product a day for 60 days, instrument-measured spot intensity fell by 2.28% versus 0.31% with placebo.
  • In healthy Japanese adults aged 40–69 with relatively low memory scores, a mixture of aqueous and CO₂ turmeric extracts showed no advantage over placebo in the primary memory test over 24 weeks.
  • In adults with knee osteoarthritis, WDTE60N at 250 mg of product a day for 90 days slightly reduced pain and eased everyday movement compared with placebo.
  • In adults with chronic knee pain without arthritis, WDTE60N at 250 mg a day for 90 days reduced pain after brisk walking by about 0.9 points out of 10 more than placebo.
  • In female students aged 18–25 with PMS and painful periods, a complex of turmeric extract and phosphatidylcholine at 500 mg a day slightly reduced pain and PMS symptoms compared with placebo. It was taken for ten days in each of two cycles; both groups were allowed ibuprofen.
  • In adults with functional dyspepsia, recurrent discomfort in the upper abdomen, the turmeric products studied reduced overall digestive complaints compared with placebo over four weeks.
  • In one functional dyspepsia trial, 500 mg capsules of the Curcuma longa preparation four times a day for four weeks slightly improved quality of life compared with placebo. The dose specifies the weight of the studied preparation, not pure curcumin.
  • After menopause, the mixture studied, providing 1000 mg of curcuminoids a day for 12 weeks, reduced hot flushes by about seven per week more than placebo. No advantage in overall quality of life or total menopause symptoms was found.
  • In people with perennial allergic rhinitis, a study of Organika curcumin reported less sneezing, runny nose and nasal congestion. The dose was 500 mg a day for two months.
  • CurQfen CGM at 250 mg a day for 28 days showed no advantage over placebo in overall symptom severity in adults with mild allergic rhinitis.
  • In men a day after unfamiliar downhill running, more strength was retained in a knee-extension test with the turmeric preparation studied than with placebo. The dose was 300 mg of product a day, containing 90 mg of curcuminoids, for five days.
  • In adults with type 2 diabetes, different turmeric and curcumin products over 8–36 weeks produced small differences compared with control: weight was on average 1.9 kg lower and waist circumference 1.9 cm smaller. In prediabetes, the weight difference in the same review was about 2.5 kg.
  • In healthy men at high altitude, curcumin at 812 mg a day for seven weeks showed no convincing advantage over placebo in reducing body fat percentage or increasing muscle mass.
  • In adults with prediabetes or type 2 diabetes, a review of different turmeric and curcumin products found systolic blood pressure on average about 2.7 mmHg lower than in control groups. No convincing difference in diastolic pressure was found.
  • In people with diabetic retinal damage without new vessel growth, the combination of 1000 mg of curcumin and 10 mg of piperine a day for 12 weeks slightly improved the sleep score compared with placebo.
  • In a review of adults with different health conditions, including people taking antidepressants, different turmeric and curcumin products reduced depressive symptoms, anxiety and stress compared with placebo. Results varied greatly between products and participant groups.

[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17]

What was studied

  • Specific products were studied for knee and muscle pain, digestive complaints, menstrual symptoms, hot flushes and allergic rhinitis.
  • Sleep, mood, weight and blood pressure were also tested; some results came from people with prediabetes, type 2 diabetes and a diabetic eye complication.
  • Several measures from one trial concern the same participant group; reviews may include the same trials. Each outcome below separately specifies its source, group, form, dose, duration and comparison.

[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17]

Which forms were considered

  • Supplements contain rhizome powder, curcumin and different standardised extracts; check the label for composition.
  • Studies used different products: 250 mg of WDTE60N contained 150 mg of curcuminoids, while Curcugen was taken at 500 mg of product a day.

[1] [2] [3]

How to get it from food

  • Ground turmeric is used as a seasoning in food.
  • One teaspoon of ground turmeric contains about 3 g of spice and 9 kcal, a useful guide for a culinary serving.

[1] [2]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Muscle pain after strength exerciseMuscle pain during the four days after strength exercise involving squats was lower with WDTE60N than with placebo.Total VAS pain measure over 0–96 hours: 286.8±46.7 with WDTE60N versus 460.0±40.5 with placebo; p<0.0001.
1/4 Very lowPrecision of the estimate: The CI of the direct contrast was not extracted or concerns group means. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Exact protocol and specific formulation. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small groups, several outcomes or completer analysis.
11 randomised trialEfficacy of TurmXTRA® 60N in Delayed Onset Muscle Soreness in Healthy, Recreationally Active Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial ↗30 healthy moderately active adults aged 18–35, 15 per group
  1. Efficacy of TurmXTRA® 60N in Delayed Onset Muscle Soreness in Healthy, Recreationally Active Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
Overall digestive complaint score (GSRS)The overall digestive complaint score decreased more with Curcugen than with placebo over eight weeks.mean 2.91→2.10 versus 2.65→2.18; group×time interaction p=0.021, ES 0.57
2/4 LowPrecision of the estimate: No CI of the direct contrast in the extraction. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow study question. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small sample and authors linked to the manufacturer.
11 randomised trial (79 randomised, 77 with questionnaire data; overall score and subscales in one trial)Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study ↗79 adults with self-rated gastrointestinal complaints, 38 and 39 with questionnaire data
  1. Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study ↗
Individual digestive symptoms and overall quality of lifeNo advantage of Curcugen over placebo was found for individual types of digestive complaints or overall quality of life.the authors found no significant group interactions for individual subscales or overall quality of life; abdominal pain p=0.124
1/4 Very lowPrecision of the estimate: The CI of the direct contrast was not extracted or concerns group means. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Exact protocol and specific formulation. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small groups, several outcomes or completer analysis.
11 randomised trial (79 randomised, 77 with questionnaire data; overall score and subscales in one trial)Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study ↗77 adults with self-reported digestive complaints
  1. Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Daily intake requirements and upper limits

Intake and studied regimens
ContextInformation
Intake and studied regimensIn studies, 250 mg of WDTE60N contained 150 mg of curcuminoids; Curcugen was used at 500 mg of product a day. Finished product, extract, curcuminoid and added piperine weights on the label are different quantities.

Efficacy of TurmXTRA® 60N in Delayed Onset Muscle Soreness in Healthy, Recreationally Active Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study ↗

Forms

Curcuma longa rhizome powder, curcumin, standardised extracts and piperine formulations differ in composition; a specific product's results concern its own form.

Guidance for each goal

Muscle pain after strength exercise1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: The CI of the direct contrast was not extracted or concerns group means. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Exact protocol and specific formulation. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small groups, several outcomes or completer analysis.

Muscle pain during the four days after strength exercise involving squats was lower with WDTE60N than with placebo.

Study findings. Muscle pain during the four days after strength exercise involving squats was lower with WDTE60N than with placebo.

Studied regimen250 mg of product/dayoral water-dispersible WDTE60N extract, 60% curcuminoids
Duration and population33 days: the first 29 days before and on the exercise day, the next 4 days after exercise30 healthy moderately active adults aged 18–35, 15 per group

Comparison: placebo

Overall digestive complaint score (GSRS)2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: No CI of the direct contrast in the extraction. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow study question. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small sample and authors linked to the manufacturer.

The overall digestive complaint score decreased more with Curcugen than with placebo over eight weeks.

Study findings. The overall digestive complaint score decreased more with Curcugen than with placebo over eight weeks.

Studied regimen500 mg of product/dayoral Curcugen extract, 50% curcuminoids in the formulation
Duration and population8 weeks79 adults with self-rated gastrointestinal complaints, 38 and 39 with questionnaire data

Comparison: placebo

Individual digestive symptoms and overall quality of life1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: The CI of the direct contrast was not extracted or concerns group means. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Exact protocol and specific formulation. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small groups, several outcomes or completer analysis.

No advantage of Curcugen over placebo was found for individual types of digestive complaints or overall quality of life.

Study findings. No advantage of Curcugen over placebo was found for individual types of digestive complaints or overall quality of life.

Studied regimen500 mg of product a dayoral Curcugen extract, 50% curcuminoids in the formulation
Duration and population8 weeks77 adults with self-reported digestive complaints

Comparison: placebo

Primary Cognitrax memory score2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: 40 participants, CI of the primary contrast not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow study question. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Manufacturer links and many secondary outcomes.

After 24 weeks, no advantage of the extract mixture over placebo was found for the primary memory score.

Study findings. After 24 weeks, no advantage of the extract mixture over placebo was found for the primary memory score.

Studied regimen2 capsules a day: 0.96 g of finished preparation, 400 µg of bisacurone and 100 µg each of turmeronols A and Boral mixture of aqueous and CO₂ Curcuma longa extracts with bisacurone and turmeronols
Duration and population24 weeks40 healthy Japanese adults aged 40–69 with relatively low memory scores, 20 versus 20

Comparison: placebo

instrument-measured spot intensity1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: CI of the contrast not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: One instrument-measured outcome for a specific product. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Attrition, manufacturer and multiple outcomes.

After 60 days, instrument-measured spot intensity fell by 2.28% with WDTE60N versus 0.31% with placebo in the 90 women who completed the study.

Study findings. After 60 days, instrument-measured spot intensity fell by 2.28% with WDTE60N versus 0.31% with placebo in the 90 women who completed the study.

Studied regimen250 mg/day, 150 mg of curcuminoidsoral water-dispersible WDTE60N extract
Duration and population60 days96 healthy women aged 18–40 with facial spots, 45 and 45 completed

Comparison: placebo

hydration by MoistureMeterSC1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: 90 completed, CI of the contrast absent. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Instrument-measured outcome in women with facial spots. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Completer analysis, several measures and manufacturer links.

After 60 days, the instrument-measured hydration value changed from 19.31 to 24.47 with WDTE60N and from 19.46 to 17.27 with placebo in the 90 women who completed the study.

Study findings. After 60 days, the instrument-measured hydration value changed from 19.31 to 24.47 with WDTE60N and from 19.46 to 17.27 with placebo in the 90 women who completed the study.

Studied regimen250 mg of product a day, including 150 mg of curcuminoidsoral WDTE60N, 60% curcuminoids
Duration and population60 days96 healthy women aged 18–40 with a facial spot, 45 and 45 completed

Comparison: placebo

Knee pain in osteoarthritis: WDTE60N2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Exact CI of the difference not reported, magnitude small relative to the scale. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow PICO. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Completer analysis, manufacturer funding.

Knee pain decreased more with WDTE60N than with placebo over 90 days: an additional reduction of about 8.39 mm on a 0–100 mm scale.

Study findings. Knee pain decreased more with WDTE60N than with placebo over 90 days: an additional reduction of about 8.39 mm on a 0–100 mm scale.

Studied regimen250 mg of product/day, about 150 mg of curcuminoidsoral water-dispersible WDTE60N extract, 60% curcuminoids
Duration and population90 days140 randomised adults with knee osteoarthritis, 139 completed: 70 and 69

In the RCT studied, VAS fell more with WDTE60N. Comparison: placebo; NSAIDs prohibited, rescue paracetamol allowed

Pain after walking in chronic knee pain without arthritis2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Exact CI of the difference absent. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow PICO. Possible publication bias: There are no specific data for a separate downgrade. Study methods: 10 of 106 dropped out, sponsored study.

In adults with chronic knee pain without radiographic arthritis, pain after brisk walking fell by about 0.9 points out of 10 more with WDTE60N than with placebo.

Study findings. In adults with chronic knee pain without radiographic arthritis, pain after brisk walking fell by about 0.9 points out of 10 more with WDTE60N than with placebo.

Studied regimen250 mg/day, 150 mg of curcuminoidsoral water-dispersible WDTE60N extract
Duration and population90 days106 adults aged 18–60 with chronic knee pain without radiographic arthritis; 49 and 47 completed

In the RCT studied, pain after brisk walking decreased more with WDTE60N. Comparison: placebo, rescue analgesics allowed

Menstrual pain1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: 62 women, CI allows a small change. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Comparison of an extract–phosphatidylcholine complex; not transferable to an individual component. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Multiple time points and scales, ibuprofen consumption not fully measured.

In the second cycle, pain was on average 0.8 points out of 10 lower with the extract–phosphatidylcholine complex than with placebo; both groups could use the ibuprofen provided.

Study findings. In the second cycle, pain was on average 0.8 points out of 10 lower with the extract–phosphatidylcholine complex than with placebo; both groups could use the ibuprofen provided.

Studied regimen500 mg capsule/day for 10 days of each of two cyclesoral Curcuma longa extract with phosphatidylcholine
Duration and population2 treatment cycles; third cycle follow-up62 female students aged 18–25 with PMS and primary dysmenorrhoea, 31 versus 31

In the second cycle, a decrease in this measure was recorded in the studied group with the specific complex. Comparison: placebo; both groups could take the ibuprofen provided

Premenstrual syndrome symptoms1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: 62 women, CI allows a small change. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Comparison of an extract–phosphatidylcholine complex; not transferable to an individual component. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Multiple time points and scales, ibuprofen consumption not fully measured.

In the second cycle, the overall PMS symptom score was lower with the extract–phosphatidylcholine complex than with placebo.

Study findings. In the second cycle, the overall PMS symptom score was lower with the extract–phosphatidylcholine complex than with placebo.

Studied regimen500 mg capsule/day for 10 days of each of two cyclesoral Curcuma longa extract with phosphatidylcholine
Duration and population2 treatment cycles; third cycle follow-up62 female students aged 18–25 with PMS and primary dysmenorrhoea, 31 versus 31

In the second cycle, a decrease in this measure was recorded in the studied group with the specific complex. Comparison: placebo; both groups could take the ibuprofen provided

Overall functional dyspepsia symptoms3/4 ModerateRead moreCollapse
Confidence
3/4 ModeratePrecision of the estimate: Enough data for a limited conclusion. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow PICO. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Two small trials and limited reproducibility.

A review of two trials reported a reduction in the overall functional dyspepsia symptom score with the products studied compared with placebo over four weeks.

Study findings. A review of two trials reported a reduction in the overall functional dyspepsia symptom score with the products studied compared with placebo over four weeks.

Studied regimendoses from different studies; in Yongwatana, 500 mg 4 times a daydifferent oral Curcuma longa preparations
Duration and population4 weeks110 adults with functional dyspepsia in 2 RCTs

The review showed a reduction in the overall dyspepsia index with the preparations studied.

Sleep quality in diabetic retinopathy1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: 56 completed, exact CI of the effect not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Combination with piperine in patients with retinopathy. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Inconsistent reporting of sex, several outcomes.

In patients with non-proliferative diabetic retinopathy, the curcumin–piperine combination slightly improved the PSQI sleep score compared with placebo over 12 weeks.

Study findings. In patients with non-proliferative diabetic retinopathy, the curcumin–piperine combination slightly improved the PSQI sleep score compared with placebo over 12 weeks.

Studied regimen1000 mg of curcumin + 10 mg of piperine/dayoral curcumin plus piperine alongside usual care
Duration and population12 weeks60 patients with non-proliferative diabetic retinopathy randomised; 56 completed

A small difference was observed in the specific clinical group and mixture; the isolated contribution of curcumin and its effect in ordinary insomnia have not been established.

Systolic blood pressure in prediabetes or T2DM1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: The interval allows a small effect or no effect. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Different forms, some mixtures; patients with dysglycaemia were studied. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Limited quality of individual RCTs.

In the review, adults with prediabetes or T2DM had systolic blood pressure on average 2.69 mmHg lower with the products studied than with control.

Study findings. In the review, adults with prediabetes or T2DM had systolic blood pressure on average 2.69 mmHg lower with the products studied than with control.

Studied regimendoses and formulations varydifferent oral turmeric/curcumin products, including mixtures
Duration and populationdurations vary855 adults with prediabetes or type 2 diabetes, 15 RCTs

The pooled estimate showed a small reduction in systolic blood pressure. Comparison: control in the relevant RCTs alongside usual care

Diastolic blood pressure in prediabetes or T2DM1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: The interval allows a small effect or no effect. Consistency of results: I²=84.3%. Applicability to the stated group: Different forms, some mixtures; patients with dysglycaemia were studied. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Limited quality of individual RCTs.

The review found no convincing difference in diastolic blood pressure between the products studied and control.

Study findings. The review found no convincing difference in diastolic blood pressure between the products studied and control.

Studied regimendoses and formulations varydifferent oral turmeric/curcumin products, including mixtures
Duration and populationdurations vary855 adults with prediabetes or type 2 diabetes, 15 RCTs

No convincing change in diastolic blood pressure was established. Comparison: control in the relevant RCTs alongside usual care

Body weight in T2DM1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Uncertain transferability of the magnitude to an individual product. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Different forms and the T2DM clinical group. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small, differing trials.

In the subgroup of adults with T2DM, body weight was on average 1.9 kg lower with the products studied than with control.

Study findings. In the subgroup of adults with T2DM, body weight was on average 1.9 kg lower with the products studied than with control.

Studied regimen80–2100 mg/day in the reviewdifferent oral curcumin/turmeric preparations
Duration and population8–36 weeksadults with type 2 diabetes in a subgroup of the review of 20 RCTs/1387 total participants

Heterogeneous laboratory and anthropometric findings do not guarantee an effect from a specific product or in healthy people. Comparison: control in the relevant RCT

Waist circumference in T2DM1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Uncertain transferability of the magnitude to an individual product. Consistency of results: Very high heterogeneity. Applicability to the stated group: Different forms and the T2DM clinical group. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small, differing trials.

In the subgroup of adults with T2DM, waist circumference was on average 1.9 cm smaller with the products studied than with control.

Study findings. In the subgroup of adults with T2DM, waist circumference was on average 1.9 cm smaller with the products studied than with control.

Studied regimen80–2100 mg/day in the reviewdifferent oral curcumin/turmeric preparations
Duration and population8–36 weeksadults with type 2 diabetes in a subgroup of the review of 20 RCTs/1387 total participants

Heterogeneous laboratory and anthropometric findings do not guarantee an effect from a specific product or in healthy people. Comparison: control in the relevant RCT

Body mass index in T2DM1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Uncertain transferability of the magnitude to an individual product. Consistency of results: Very high heterogeneity. Applicability to the stated group: Different forms and the T2DM clinical group. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small, differing trials.

In the subgroup of adults with T2DM, no convincing difference in body mass index between the products studied and control was found.

Study findings. In the subgroup of adults with T2DM, no convincing difference in body mass index between the products studied and control was found.

Studied regimen80–2100 mg/day in the reviewdifferent oral curcumin/turmeric preparations
Duration and population8–36 weeksadults with type 2 diabetes in a subgroup of the review of 20 RCTs/1387 total participants

Heterogeneous laboratory and anthropometric findings do not guarantee an effect from a specific product or in healthy people. Comparison: control in the relevant RCT

Body weight in prediabetes1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: The interval is close to zero. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Different formulations; prediabetes only. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Limitations of the primary RCTs.

In the subgroup of adults with prediabetes, body weight was on average 2.5 kg lower with the products studied than with control.

Study findings. In the subgroup of adults with prediabetes, body weight was on average 2.5 kg lower with the products studied than with control.

Studied regimen80–2100 mg of different products a day80–2100 mg of different products a day
Duration and population8–36 weeksAdults with prediabetes in a subgroup of the review of 20 RCTs/1387 total participants

The pooled signal concerns participants with prediabetes. Comparison: Control

Everyday knee function in osteoarthritis1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: The CI of the direct contrast was not extracted or concerns group means. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Exact protocol and specific formulation. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small groups, several outcomes or completer analysis.

In knee osteoarthritis, the KOOS ADL everyday function score improved more with WDTE60N than with placebo over 90 days.

Study findings. In knee osteoarthritis, the KOOS ADL everyday function score improved more with WDTE60N than with placebo over 90 days.

Studied regimen250 mg of product/dayoral water-dispersible WDTE60N extract, 60% curcuminoids
Duration and population90 days140 randomised adults with knee osteoarthritis, 70 and 69 completed

In the specific RCT, the functional scale improved more than with placebo; intervals concern group mean changes, not their difference. Comparison: placebo; NSAIDs prohibited, rescue paracetamol allowed

Time to walk 80 metres in chronic knee pain1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: The CI of the direct contrast was not extracted or concerns group means. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Exact protocol and specific formulation. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small groups, several outcomes or completer analysis.

Time to walk 80 metres briskly decreased more with WDTE60N than with placebo according to the authors; the table has an unusual relationship between means and medians.

Study findings. Time to walk 80 metres briskly decreased more with WDTE60N than with placebo according to the authors; the table has an unusual relationship between means and medians.

Studied regimen250 mg/dayoral WDTE60N, 150 mg of curcuminoids
Duration and population90 days106 adults with chronic knee pain without radiographic arthritis, 49 and 47 completed

Time changed in the specific trial, but the imprecise and unusual distribution requires caution when extrapolating.

Depressive symptoms in different adult groups1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Uncertain effect size in a specific group. Consistency of results: I² approximately 95% or higher. Applicability to the stated group: Heterogeneous clinical populations and products. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Authors' GRADE described differently across sections, RCT limitations.

The review reported fewer depressive symptoms than with placebo in mixed adult groups; marked heterogeneity prevents predicting the benefit size for an individual.

Study findings. The review reported fewer depressive symptoms than with placebo in mixed adult groups; marked heterogeneity prevents predicting the benefit size for an individual.

Studied regimendoses and forms varydifferent oral curcumin/turmeric products, including mixtures
Duration and populationstudy durations varyDifferent adult populations, including patients taking antidepressants; 1491 participants/26 RCTs concern the whole review, not just this outcome.

Marked heterogeneity and mixed populations prevent predicting individual benefit size. The authors' GRADE is described inconsistently across article sections. Comparison: placebo in the included RCTs

Anxiety symptoms in different adult groups1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Uncertain effect size in a specific group. Consistency of results: I² approximately 95% or higher. Applicability to the stated group: Heterogeneous clinical populations and products. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Authors' GRADE described differently across sections, RCT limitations.

The review reported fewer anxiety symptoms than with placebo in mixed adult groups; marked heterogeneity prevents predicting the benefit size for an individual.

Study findings. The review reported fewer anxiety symptoms than with placebo in mixed adult groups; marked heterogeneity prevents predicting the benefit size for an individual.

Studied regimendoses and forms varydifferent oral curcumin/turmeric products, including mixtures
Duration and populationstudy durations varyDifferent adult populations, including patients taking antidepressants; 1491 participants/26 RCTs concern the whole review, not just this outcome.

Marked heterogeneity and mixed populations prevent predicting individual benefit size. The authors' GRADE is described inconsistently across article sections. Comparison: placebo in the included RCTs

Stress symptoms in different adult groups1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Uncertain effect size in a specific group. Consistency of results: I² approximately 95% or higher. Applicability to the stated group: Heterogeneous clinical populations and products. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Authors' GRADE described differently across sections, RCT limitations.

The review reported lower stress scores than with placebo in mixed adult groups; marked heterogeneity prevents predicting the benefit size for an individual.

Study findings. The review reported lower stress scores than with placebo in mixed adult groups; marked heterogeneity prevents predicting the benefit size for an individual.

Studied regimendoses and forms varydifferent oral curcumin/turmeric products, including mixtures
Duration and populationstudy durations varyDifferent adult populations, including patients taking antidepressants; 1491 participants/26 RCTs concern the whole review, not just this outcome.

Marked heterogeneity and mixed populations prevent predicting individual benefit size. The authors' GRADE is described inconsistently across article sections. Comparison: placebo in the included RCTs

Overall nasal symptoms: CurQfen CGM1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: CI of the direct contrast not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The formulation contains a fenugreek matrix. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Three groups, several outcomes and a sponsor's product.

CurQfen CGM showed no convincing advantage over placebo in the overall nasal symptom score over 28 days.

Study findings. CurQfen CGM showed no convincing advantage over placebo in the overall nasal symptom score over 28 days.

Studied regimen1 capsule of 250 mg of CurQfen product with 95±5 mg of curcuminoids a dayoral CurQfen CGM, curcuminoids in a fenugreek matrix; a separate group also contains ashwagandha
Duration and population28 daysadults with mild allergic rhinitis in a three-arm RCT

The single extract showed no clear change in overall TNSS; the positive arm with ashwagandha is not an effect of turmeric alone.

Sneezing in perennial allergic rhinitis1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: No numerical contrast or CI. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Perennial rhinitis and the specific curcumin only. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Full text and randomisation details unavailable.

The primary abstract of the perennial allergic rhinitis study reports improved sneezing when comparing the curcumin studied with placebo over two months; the numerical between-group difference is not stated in the available abstract.

Study findings. The primary abstract of the perennial allergic rhinitis study reports improved sneezing when comparing the curcumin studied with placebo over two months; the numerical between-group difference is not stated in the available abstract.

Studied regimen500 mg once a dayOral Organika curcumin 500 mg once a day
Duration and populationTwo months241 patients with perennial allergic rhinitis

A signal was reported for an individual rhinitis outcome in one study.

Runny nose in perennial allergic rhinitis1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: No numerical contrast or CI. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Perennial rhinitis and the specific curcumin only. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Full text and randomisation details unavailable.

The primary abstract of the perennial allergic rhinitis study reports improved runny nose when comparing the curcumin studied with placebo over two months; the numerical between-group difference is not stated in the available abstract.

Study findings. The primary abstract of the perennial allergic rhinitis study reports improved runny nose when comparing the curcumin studied with placebo over two months; the numerical between-group difference is not stated in the available abstract.

Studied regimen500 mg once a dayOral Organika curcumin 500 mg once a day
Duration and populationTwo months241 patients with perennial allergic rhinitis

A signal was reported for an individual rhinitis outcome in one study.

Nasal congestion in perennial allergic rhinitis1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: No numerical contrast or CI. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Perennial rhinitis and the specific curcumin only. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Full text and randomisation details unavailable.

The primary abstract of the perennial allergic rhinitis study reports improved nasal congestion when comparing the curcumin studied with placebo over two months; the numerical between-group difference is not stated in the available abstract.

Study findings. The primary abstract of the perennial allergic rhinitis study reports improved nasal congestion when comparing the curcumin studied with placebo over two months; the numerical between-group difference is not stated in the available abstract.

Studied regimen500 mg once a dayOral Organika curcumin 500 mg once a day
Duration and populationTwo months241 patients with perennial allergic rhinitis

A signal was reported for an individual rhinitis outcome in one study.

Nasal airflow resistance in perennial allergic rhinitis1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: No numerical contrast or CI. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Perennial rhinitis and the specific curcumin only. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Full text and randomisation details unavailable.

The primary abstract of the perennial allergic rhinitis study reports improved nasal airflow resistance when comparing the curcumin studied with placebo over two months; the numerical between-group difference is not stated in the available abstract.

Study findings. The primary abstract of the perennial allergic rhinitis study reports improved nasal airflow resistance when comparing the curcumin studied with placebo over two months; the numerical between-group difference is not stated in the available abstract.

Studied regimen500 mg once a dayOral Organika curcumin 500 mg once a day
Duration and populationTwo months241 patients with perennial allergic rhinitis

A signal was reported for an individual rhinitis outcome in one study.

Hot flush frequency after menopause2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: CI allows a change of about one hot flush a day or less. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow PICO. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Retrospective registration, small pilot.

In postmenopausal women, the standardised mixture studied reduced hot flush frequency by about seven per week more than placebo over 12 weeks.

Study findings. In postmenopausal women, the standardised mixture studied reduced hot flush frequency by about seven per week more than placebo over 12 weeks.

Studied regimen4 capsules, each with 294.12 mg of extract containing 250 mg of curcuminoids; 1000 mg of curcuminoids/dayoral standardised turmeric extract with a curcuminoid mixture
Duration and population12 weeks40 postmenopausal women aged 41–65, double-blind pilot RCT

Over 12 weeks, the specific standardised mixture reduced hot flush numbers in this pilot study.

Quality of life after menopause: MENQOL2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Small sample, exact CI of the contrast not confirmed. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow PICO. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Retrospectively registered pilot with several secondary outcomes.

At week 12, no advantage of the mixture studied over placebo was found for overall MENQOL quality of life.

Study findings. At week 12, no advantage of the mixture studied over placebo was found for overall MENQOL quality of life.

Studied regimen1000 mg of curcuminoids/daystandardised turmeric extract, 4 capsules
Duration and population12 weeksThe same 40 postmenopausal women aged 41–65 from the hot_flash trial.

No advantage on the overall scale was established.

Overall menopause symptoms: MRS II2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Small sample, exact CI of the contrast not confirmed. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow PICO. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Retrospectively registered pilot with several secondary outcomes.

At week 12, no advantage of the mixture studied over placebo was found for the overall MRS II symptom score.

Study findings. At week 12, no advantage of the mixture studied over placebo was found for the overall MRS II symptom score.

Studied regimen1000 mg of curcuminoids/daystandardised turmeric extract, 4 capsules
Duration and population12 weeksThe same 40 postmenopausal women aged 41–65 from the hot_flash trial.

No advantage on the overall scale was established.

Preservation of knee-extension strength after downhill running in men1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: The CI of the direct contrast was not extracted or concerns group means. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Exact protocol and specific formulation. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small groups, several outcomes or completer analysis.

In men a day after downhill running, the loss of peak knee-extension torque was smaller with the colloidal formulation studied than with placebo; this is a secondary test in one crossover trial.

Study findings. In men a day after downhill running, the loss of peak knee-extension torque was smaller with the colloidal formulation studied than with placebo; this is a secondary test in one crossover trial.

Studied regimen300 mg/day, 90 mg of curcuminoidsoral colloidal turmeric formulation
Duration and population5 days; downhill run on day 234 men in a crossover RCT, 44 active adults in total

One secondary test in men showed a smaller torque loss; primary soreness measures were inconclusive, and extrapolation to other exercise is unknown.

Change in body fat percentage in men at high altitude1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Exact CI of the effect not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Men at high altitude, BIA is an indirect method. Possible publication bias: There are no specific data for a separate downgrade. Study methods: 12 dropped out, several BIA measures.

In men at high altitude, the overall group×time analysis showed no convincing difference in body fat percentage change; individual positive tests do not establish a fat-loss advantage.

Study findings. In men at high altitude, the overall group×time analysis showed no convincing difference in body fat percentage change; individual positive tests do not establish a fat-loss advantage.

Studied regimen812 mg/dayoral chewable curcumin formulation
Duration and population1 preparatory week and 6 weeks at high altitude102 healthy Han Chinese men aged 18–45 randomised, 44 and 46 completed

A measurement in specific high-altitude conditions does not substantiate weight loss in healthy people in an ordinary environment; BIA is an indirect estimate. Comparison: placebo

Fat-free and muscle mass in men at high altitude1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Exact CI of the effect not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Men at high altitude, BIA is an indirect method. Possible publication bias: There are no specific data for a separate downgrade. Study methods: 12 dropped out, several BIA measures.

In men at high altitude, total fat-free mass and muscle mass increased in both groups; no convincing advantage of curcumin over placebo was found.

Study findings. In men at high altitude, total fat-free mass and muscle mass increased in both groups; no convincing advantage of curcumin over placebo was found.

Studied regimen812 mg/dayoral chewable curcumin formulation
Duration and population7 weeks102 healthy Han Chinese men aged 18–45 randomised, 44 and 46 completed; the same high-altitude sample as fat_altitude.

No convincing overall advantage in fat-free or muscle mass was shown, although small effects cannot be ruled out.

Quality of life in functional dyspepsia: EQ-5D3/4 ModerateRead moreCollapse
Confidence
3/4 ModeratePrecision of the estimate: 89 participants; CI allows a very small improvement; the threshold noticeable to an individual was not tested. Consistency of results: One RCT; between-study heterogeneity cannot be assessed. Applicability to the stated group: The conclusion is limited to the exact population, capsules, duration and EQ-5D; other forms are not equated. Possible publication bias: Not established from one trial; no specific reason for a separate downgrade. Study methods: Specific secondary-source information is available on randomisation, concealment, blinding, data completeness and concordance of outcomes with the registry; no serious defect in this contrast has been established.

In adults with functional dyspepsia, the capsules studied gave a small average improvement in EQ-5D quality of life after four weeks compared with placebo.

Study findings. In adults with functional dyspepsia, the capsules studied gave a small average improvement in EQ-5D quality of life after four weeks compared with placebo.

Studied regimenAccording to the review: 1 capsule of 500 mg 4 times a day after meals and before bed; do not describe this as 2 g of pure curcumin or curcuminoids.The oral Curcuma longa preparation capsules studied, called curcumin in the review; exact specification/standardisation not established.
Duration and population4 weeks89 adults aged 18–80 with RomeIV functional dyspepsia in two relevant arms of one Thai RCT; 45 in the studied arm, 44 on placebo.

In adults with functional dyspepsia, the capsules studied gave a small average improvement in EQ-5D quality of life after four weeks relative to placebo: difference 0.05 points (95% CI 0.01–0.09). Comparison: Matching placebo in identical capsules; both groups received omeprazole placebo. The third active omeprazole arm is not part of this contrast.

Safety and limitations

The DILIN series describes 10 cases of liver injury associated with turmeric supplements; a case series does not provide the risk frequency. Turmeric and curcumin supplements may cause nausea, reflux, diarrhoea or constipation. The TGA warns of rare, sometimes severe liver injury from turmeric or curcumin supplements. Risk may be higher with enhanced-absorption supplements or at high doses. If jaundice, dark urine or unusual weakness occurs, stop taking the supplement and seek medical help; avoid such supplements with current or past liver disease. A trial of a fenugreek, ginger and turmeric mixture does not establish the safety of a standalone turmeric supplement during lactation. Turmeric supplements during pregnancy may be unsafe; safety of amounts above food quantities during breastfeeding is little studied.

Liver Injury Associated with Turmeric: Ten Cases from DILIN ↗ · NCCIH Turmeric: Usefulness and Safety ↗ · TGA Medicines containing turmeric or curcumin - risk of liver injury ↗ · Effects of Fenugreek, Ginger, and Turmeric Supplementation on Human Milk Volume and Nutrient Content in Breastfeeding Mothers: A Randomized Double-Blind Controlled Trial ↗

Interactions

WithEffectActionSource
TamoxifenIn a small study, curcumin with piperine reduced endoxifen exposure; the reduction with curcumin without piperine was less certain.Discuss turmeric or curcumin supplements with your oncologist before taking them.Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen ↗
Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen ↗
WarfarinA substantial increase in INR and a risk of bleeding were reported with a turmeric supplement; frequency cannot be determined from one case.Before taking the supplement, discuss it with the doctor managing warfarin and agree on INR monitoring.Medsafe: Beware turmeric/curcumin containing products can interact with warfarin ↗

Food sources

The table gives the weight of the whole dried and ground spice. The USDA reference serving is one teaspoon, 3 g; its calories were calculated from the same record's data per 100 g.

Turmeric as a seasoning

Turmeric rhizome is used as a culinary spice; ordinary food use differs from concentrated supplements.

TGA Medicines containing turmeric or curcumin - risk of liver injury ↗

Food composition

FoodGroupAmountServingCaloriesSources
Turmericrhizome, dried and groundSpices100 g of ground turmeric (spice weight) / 100 g3 g · 3 g of ground turmeric (spice weight) · 9.36 kcalUSDA: 1 teaspoon of ground turmeric is 3 g.312 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 02 ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
Efficacy of TurmXTRA® 60N in Delayed Onset Muscle Soreness in Healthy, Recreationally Active Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial ↗Muscle pain after strength exercise30 healthy moderately active adults aged 18–35, 15 per grouporal water-dispersible WDTE60N extract, 60% curcuminoids; 250 mg of product/day; 33 days: the first 29 days before and on the exercise day, the next 4 days after exercise; comparison: placeboMuscle pain during the four days after strength exercise involving squats was lower with WDTE60N than with placebo.
Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study ↗Overall digestive complaint score (GSRS): Overall digestive complaint score (GSRS) Individual digestive symptoms and overall quality of life: Individual digestive symptoms and overall quality of lifeOverall digestive complaint score (GSRS): 79 adults with self-rated gastrointestinal complaints, 38 and 39 with questionnaire data Individual digestive symptoms and overall quality of life: 77 adults with self-reported digestive complaintsOverall digestive complaint score (GSRS): oral Curcugen extract, 50% curcuminoids in the formulation; 500 mg of product/day; 8 weeks; comparison: placebo Individual digestive symptoms and overall quality of life: oral Curcugen extract, 50% curcuminoids in the formulation; 500 mg of product a day; 8 weeks; comparison: placeboOverall digestive complaint score (GSRS): The overall digestive complaint score decreased more with Curcugen than with placebo over eight weeks. Individual digestive symptoms and overall quality of life: No advantage of Curcugen over placebo was found for individual types of digestive complaints or overall quality of life.

Sources

Sources
  1. Efficacy of TurmXTRA® 60N in Delayed Onset Muscle Soreness in Healthy, Recreationally Active Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
  2. Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study ↗
  3. Effects of Curcuma longa extract on cognitive function in healthy participants with subtle cognitive weaknesses within the normal range: a randomized, double-blind, placebo-controlled trial ↗
  4. Efficacy and Safety of an Oral Low-Dose Water-Dispersible Turmeric Extract Capsule on Facial Skin Health in Healthy Women: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
  5. Liver Injury Associated with Turmeric: Ten Cases from DILIN ↗
  6. Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen ↗
  7. Medsafe: Beware turmeric/curcumin containing products can interact with warfarin ↗
  8. Effects of Fenugreek, Ginger, and Turmeric Supplementation on Human Milk Volume and Nutrient Content in Breastfeeding Mothers: A Randomized Double-Blind Controlled Trial ↗
  9. NCCIH Turmeric: Usefulness and Safety ↗
  10. TGA Medicines containing turmeric or curcumin - risk of liver injury ↗
  11. Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen ↗
  12. USDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 02 ↗
  13. Non-Chinese herbal medicines for functional dyspepsia ↗
  14. Curcuminoid supplementation for vasomotor symptoms in postmenopausal women: a pilot, randomized, double-blind, placebo-controlled proof-of-concept trial ↗
  15. The effect of oral curcumin capsules on symptoms of premenstrual syndrome and dysmenorrhea: a randomized controlled trial ↗
  16. Efficacy and Safety of a Novel Low-Dose Water-Dispersible Turmeric Extract in the Management of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial ↗
  17. Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials ↗
  18. Effects of curcumin on depression, anxiety, and stress symptoms in adults: a GRADE-assessed systematic review and dose–response meta-analysis ↗
  19. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Assessing Efficacy and Safety of a Novel Low-Dose Turmeric Extract Formulation in Healthy Adults with Chronic Knee Pain ↗
  20. Effect of curcumin on nasal symptoms and airflow in patients with perennial allergic rhinitis. ↗
  21. The Effect of Curcumin Plus Piperine on Mental Health Status, Sleep Quality, and Anthropometric Indices in Patients with Non-Proliferative Diabetic Retinopathy: A Randomized Double-Blind Placebo-Controlled Trial. ↗
  22. Curcumin supplementation during high-altitude exposure modulates body composition and its relationship with gut microbiota: a randomized controlled trial. ↗
  23. Short-term influence of Immufen™ on mild allergic rhinitis: a randomized, double-blind, placebo-controlled study ↗
  24. The effect of turmeric/curcumin supplementation on anthropometric indices in subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. ↗
  25. A randomized, placebo-controlled, crossover clinical trial to evaluate the effect of a turmeric formulation on muscle soreness and function recovery in moderately active adults. ↗